Company news
Keymed Biosciences, Inc. news in 2025
Keymed Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.
Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum
August 27, 2025
Keymed Biosciences Announces The Latest Clinical Trial Results Of Cm336 Published In The New England Journal Of Medicine
June 16, 2025
Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine
June 11, 2025
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors
April 25, 2025
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers
April 24, 2025
The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine
April 5, 2025
Keymed Biosciences Announces Annual Results of 2024
March 26, 2025
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
February 10, 2025